#1 Clinical Trials Search in Europe

AZD0120

Clinical trials are investigating AZD0120 in people with relapsed or refractory multiple myeloma, a cancer that has returned or no longer responds to treatment. These studies aim to compare AZD0120 with standard therapy and measure how well it works and how safe it is. The main focus is on adults with this blood cancer in a Phase 3 trial.

Table of Contents

Trial overview

This clinical trial is studying AZD0120 in people with relapsed or refractory multiple myeloma.[1] The trial is designed to see how well AZD0120 works and how safe it is compared with standard therapy.[1]

Who the trial is for

The trial is for people with relapsed or refractory multiple myeloma.[1] Relapsed means the cancer came back after treatment, and refractory means the cancer did not respond well to treatment.[1]

What the study measures

The main outcome is progression-free survival (PFS), which is the time from randomisation until the cancer gets worse or the person dies from any cause, whichever happens first.[1] The trial also measures the MRD negative complete response rate at 9 months, which means the share of people who have no measurable residual disease and a complete or stringent complete response at that time point.[1]

Treatments being compared

The study compares AZD0120 with standard therapy options listed as DKd, DPd, PVd, or Kd.[1] These are treatment combinations used as the control group, so the researchers can see whether AZD0120 gives better results.[1]

  • DKd is one of the standard therapy options named in the trial.[1]

  • DPd is one of the standard therapy options named in the trial.[1]

  • PVd is one of the standard therapy options named in the trial.[1]

  • Kd is one of the standard therapy options named in the trial.[1]

Study design and phase

This is an interventional study, which means the researchers give treatment and then measure the results.[1] It is a Phase 3 trial, which is a later-stage study that compares a new treatment with standard care in a larger group of people.[1] The trial has an enrollment of 508 people and is currently authorised.[1]

What the results mean for patients

The study is focused on whether AZD0120 can help people stay free from disease worsening for longer than standard treatment.[1] It also looks for deep responses, meaning the cancer is harder to detect with sensitive tests.[1] These results help show whether AZD0120 may be a better option for people whose myeloma has returned or is not responding well.[1]

Trial ID Phase Condition studied Status Enrollment
2025-523285-25-00 Phase 3 Relapsed or Refractory Multiple Myeloma Authorised 508

FAQ

  • What is AZD0120 being studied for? AZD0120 is being studied in relapsed or refractory multiple myeloma. The trial is looking at whether it works better than standard treatment and how safe it is.
  • Who can take part in the trial? The trial is for people with relapsed or refractory multiple myeloma. This means the cancer has come back after treatment or has not responded well to treatment.
  • What phase is the AZD0120 trial? The trial is Phase 3. Phase 3 studies compare a new treatment with standard care in a larger group of people.
  • What treatments are compared with AZD0120? AZD0120 is compared with standard therapy. The standard options listed are DKd, DPd, PVd, or Kd.
  • What results are the researchers measuring? The main results are progression-free survival, called PFS, and MRD negative complete response rate at 9 months. PFS means the time before the cancer gets worse or the person dies from any cause, and MRD negative means no measurable signs of disease.

Ongoing Clinical Trials on AZD0120

  • AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Norway Poland Spain

Glossary

  • Relapsed multiple myeloma: Multiple myeloma that had improved or gone away after treatment but later came back.
  • Refractory multiple myeloma: Multiple myeloma that does not respond well to treatment.
  • Multiple myeloma: A cancer of plasma cells, which are a type of white blood cell found in the bone marrow.
  • Phase 3: A later stage of clinical research that compares a new treatment with standard treatment in a larger group of people.
  • Interventional study: A trial where participants receive a treatment or treatment plan so researchers can study the results.
  • Standard therapy: The usual treatment used in medical practice for a condition.
  • Progression-free survival (PFS): The length of time during and after treatment that the cancer does not get worse.
  • MRD negative: No measurable residual disease, meaning very sensitive tests do not find signs of remaining cancer.
  • Complete response (CR): A strong treatment response where signs of the disease are no longer seen.
  • Stringent complete response (sCR): A very deep response to treatment, even more detailed than complete response.
  • Randomisation: A method that assigns people to treatment groups by chance.
  • BICR: Blinded independent central review, meaning study results are checked by independent reviewers who do not know which treatment a person received.

References